Switzerland’s Actelion Pharmaceuticals Ltd. has been a reluctant M&A target in the past, unmoved by unconfirmed approaches from several big pharma companies that most recently included Shire PLC in 2015, but this time around worries about growing competition to its key pulmonary arterial hypertension (PAH) therapies might make it more receptive to a deep-pocketed suitor.
Confirmation from the Basel-based biotech on Nov